Literature DB >> 31820197

More evidence of cannabis efficacy in restless legs syndrome.

Imad Ghorayeb1,2,3.   

Abstract

Restless legs syndrome (RLS) is one of the most disabling and sometimes painful sensorimotor ailment of the nervous system that has only in recent years become more widely accepted as a clinical disorder with its own distinct features. Usually, symptoms respond well to dopamine agonists, anticonvulsants, or opiates, but still a subset of patients remains refractory to medical therapy and/or reports serious side effects. Recently, patients' statement of a remarkable and total remission of RLS symptoms following cannabis use has been reported. Here, we confirm and extend these findings to more patients with RLS. The antinociceptive effect of marijuana has been documented in many painful neurological conditions, and the potential benefit of cannabis use in patients with refractory RLS should therefore be questioned by robust clinical trials.

Entities:  

Keywords:  Cannabis; Restless legs syndrome; To the Editor; Treatment

Year:  2019        PMID: 31820197     DOI: 10.1007/s11325-019-01978-1

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  5 in total

Review 1.  Endocannabinoids in basal ganglia circuits: implications for Parkinson disease.

Authors:  Eduardo Benarroch
Journal:  Neurology       Date:  2007-07-17       Impact factor: 9.910

2.  Cannabis for restless legs syndrome: a report of six patients.

Authors:  Thomas Megelin; Imad Ghorayeb
Journal:  Sleep Med       Date:  2017-05-31       Impact factor: 3.492

Review 3.  Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects.

Authors:  Aitziber Mendiguren; Erik Aostri; Joseba Pineda
Journal:  Life Sci       Date:  2017-11-21       Impact factor: 5.037

4.  Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.

Authors:  Michael A P Bloomfield; Celia J A Morgan; Alice Egerton; Shitij Kapur; H Valerie Curran; Oliver D Howes
Journal:  Biol Psychiatry       Date:  2013-06-29       Impact factor: 13.382

5.  Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum.

Authors:  Estefanía Moreno; Anna Chiarlone; Mireia Medrano; Mar Puigdellívol; Lucka Bibic; Lesley A Howell; Eva Resel; Nagore Puente; María J Casarejos; Juan Perucho; Joaquín Botta; Nuria Suelves; Francisco Ciruela; Silvia Ginés; Ismael Galve-Roperh; Vicent Casadó; Pedro Grandes; Beat Lutz; Krisztina Monory; Enric I Canela; Carmen Lluís; Peter J McCormick; Manuel Guzmán
Journal:  Neuropsychopharmacology       Date:  2017-01-19       Impact factor: 7.853

  5 in total
  3 in total

Review 1.  Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review.

Authors:  Hayley Worth; Daniel V O'Hara; Neeru Agarwal; David Collister; Frank Brennan; Brendan Smyth
Journal:  Clin J Am Soc Nephrol       Date:  2022-01-05       Impact factor: 10.614

Review 2.  Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far.

Authors:  Kathleen J Maddison; Christopher Kosky; Jennifer H Walsh
Journal:  Nat Sci Sleep       Date:  2022-05-18

Review 3.  Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders.

Authors:  Malvika Kaul; Phyllis C Zee; Ashima S Sahni
Journal:  Neurotherapeutics       Date:  2021-02-12       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.